Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks

OBJECTIVE: To generate comparative efficacy evidence of belimumab versus anifrolumab in SLE that can inform treatment practices. METHODS: The SLE Responder Index (SRI)-4 response at 52 weeks of belimumab versus anifrolumab was evaluated with an indirect treatment comparison. The evidence base consis...

Descripción completa

Detalles Bibliográficos
Autores principales: Neupane, Binod, Shukla, Pragya, Slim, Mahmoud, Martin, Amber, Petri, Michelle, Bertsias, George K, Kim, Alfred H J, Fanouriakis, Antonis, Levy, Roger A, Chauhan, Deven, Ballew, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186457/
https://www.ncbi.nlm.nih.gov/pubmed/37147022
http://dx.doi.org/10.1136/lupus-2023-000907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186457/
https://www.ncbi.nlm.nih.gov/pubmed/37147022
http://dx.doi.org/10.1136/lupus-2023-000907

Ejemplares similares